Stock AnalizTG Therapeutics, Inc. TGTX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
TG Therapeutics, Inc. (TGTX) is a healthcare company listed in the US with a market value of about $9.8B. In the twelve months to September 30, 2026 it had revenue of $898M and net income of $106M, a net margin of 11.8%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 96.3, a price to free cash flow of 114.0, 5-year revenue growth of 427% a year, a 5-year average ROIC of -47%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 87% below the current price.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $898M | $616M | $329M | $234M | $3M | $7M | $152000 | $152000 | $152000 | $152000 | $152000 |
| Net income | $106M | $447M | $23M | $13M | -$224M | -$348M | -$279M | -$173M | -$173M | -$118M | -$78M |
| Free cash flow | $86M | -$25M | -$41M | -$31M | -$176M | -$296M | -$215M | -$133M | -$129M | -$94M | -$62M |
| EPS (diluted) | $0.67 | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 | $-2.42 | $-1.96 | $-2.30 | $-1.91 | $-1.60 |
| Net margin | 11.8% | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | -183800.0% | -113700.0% | -114100.0% | -77944.7% | -51482.2% |
| ROIC | — | 10.8% | 8.1% | 7.4% | -154.1% | -109.0% | -48.7% | -212.9% | -723.6% | -176.9% | -219.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $69.43, 8% above the current price; targets range from $21.00 to $86.00; the consensus rating is “Strong buy”; expected EPS is $0.97 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is TG Therapeutics’s P/E ratio?
About 96.3, based on the last twelve months of diluted earnings per share (forward P/E about 26.9).
Is TG Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 87% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does TG Therapeutics pay a dividend?
Not currently.
Is TG Therapeutics a good stock to buy?
We do not give buy or sell advice. TG Therapeutics scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.